Biogen Idec commissioned Charles River Associates to examine how access to innovative treatments for multiple sclerosis (MS) varies across European countries, the factors explaining this, and the policy lessons that can be drawn. MS is a disorder of the central nervous system (brain and spinal cord) affecting over 500,000 Europeans. CRA found that significant inequalities in access to MS treatments persist in 2013. To download the PDF version of this report click the link below.
How will COVID-19 impact drug funding and reimbursement?
During the ongoing pandemic, the focus on quickly developing COVID-19 vaccines has led countries and global government bodies to make substantial investments...